[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sudden-cardiac-arrest\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sudden-cardiac-arrest":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,57,83,122,152,184,216,238,267,291,305,333,357,391],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100640694","femart-1-pilot-study-100640694",false,"NCT07596446","FEMART-1 Pilot Study","FEMART-1","Inclusion Criteria:\n\n\\* Non-traumatic out-of-hospital cardiac arrest (OHCA).\n\nPatients meeting criteria for one of the following clinical scenarios:\n\nGroup A - ECPR-like group:\n\n* Refractory cardiac arrest, including cardiac arrest occurring in the presence of the EMS crew.\n* Age 18-70 years.\n* Effective bystander cardiopulmonary resuscitation.\n* Initial rhythm of ventricular fibrillation (VF), pulseless ventricular tachycardia (pVT), or pulseless electrical activity (PEA).\n\nGroup B - post-ROSC group:\n\n* Return of spontaneous circulation (ROSC) after non-traumatic OHCA.\n* Age 18-70 years.\n\nExclusion Criteria:\n\n* Trauma as the probable primary cause of cardiac arrest.\n* Known severe comorbidity, including:\n\n  * terminal stage of incurable disease (advanced malignancy, advanced dementia, terminal pulmonary disease, terminal heart failure, or palliative care status),\n  * established do-not-resuscitate (DNR) status,\n  * severe pre-existing neurological disability (CPC 3 or CPC 4),\n  * known severe peripheral arterial disease or known occlusion of lower limb arteries,\n  * suspected pulmonary embolism with indication for thrombolytic therapy,\n  * known severe hematological disease associated with severe thrombocytopenia,\n  * morbid obesity.\n* Known or suspected pregnancy.","ALL","18 Years","70 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","The FEMART-1 Pilot Study is focused on evaluating the feasibility, safety, and procedural timing of prehospital femoral arterial sheath placement in patients with non-traumatic out-of-hospital cardiac arrest (OHCA), both during ongoing cardiopulmonary resuscitation and after return of spontaneous circulation (ROSC).\n\nThe primary objective of the study is to enable invasive arterial blood pressure monitoring for targeted and continuous hemodynamic management using vasopressor therapy in the prehospital setting. The study evaluates the feasibility, safety, and procedural performance of invasive arterial monitoring with the aim of improving assessment of the patient's hemodynamic status and enabling more accurate titration of vasopressor support. This approach may reduce episodes of hypotension and decrease the risk of recurrent cardiac arrest while allowing safer transport to specialized cardiac arrest centers.\n\nFemoral arterial access enables more precise monitoring of perfusion pressure, targeted vasopressor titration, and early recognition of impending circulatory collapse. The intervention may contribute to improved early organ perfusion and could be associated with more favorable neurological and overall clinical outcomes after cardiac arrest. In accordance with the ERC Guidelines 2025, which emphasize active hemodynamic optimization after ROSC and acknowledge the potential role of invasive arterial pressure monitoring during ongoing resuscitation, the study evaluates not only feasibility, safety, and procedural timing, but also the potential clinical benefit of continuous hemodynamic-guided management in the prehospital phase, including (1) early identification of hypotension, (2) targeted vasopressor administration, and (3) prevention of re-arrest.\n\nThe study is conducted by the Prague Air Rescue Service Kryštof 01 (Prague Emergency Medical Services) in collaboration with the Central Bohemian Emergency Medical Service, the Second Department of Internal Medicine - Cardiology and Angiology of the General University Hospital in Prague and First Faculty of Medicine, Charles University, and the Department of Anesthesiology, Resuscitation and Intensive Care Medicine of the General University Hospital in Prague and First Faculty of Medicine, Charles University.\n\nFEMART-1 is designed as a prospective pilot study without external funding.",[27,28,29],"Sudden Cardiac Arrest","Out-of-hospital Cardiac Arrest (OHCA)","Cardiogenic Shock Acute",[31,32,33,34,35,36,37,38,39,40,41,42,43],"ECPR","Femoral Arterial Sheath","Femoral Cannulation","Invasive Blood Pressure Monitoring","Prehospital Care","Emergency Medical Services","Resuscitation","Ultrasound-Guided Vascular Access","OHCA","ROSC","Hemodynamic Monitoring","Refractory Cardiac Arrest","ALS","RECRUITING","2026-05-18",{"date":47,"type":48},"2026-05-20","ACTUAL",{"date":50,"type":21},"2026-05-11",{"date":52,"type":21},"2027-03-30",{"name":54,"class":55},"Emergency Medical Service, Prague","OTHER_GOV",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":56},"100533715","developing-and-testing-drone-delivered-aeds-for-cardiac-arrests-in-rural-america-100533715","NCT06229418","Developing and Testing Drone-Delivered AEDs for Cardiac Arrests In Rural America","RESTORe-CARE","Inclusion Criteria:\n\n* Patients 18 years of age or older in the CARES registry who suffer cardiac arrest before arrival of a 911-responder of non-traumatic cause, including patients who receive an AED shock by a bystander prior to the arrival of 911 responders.\n\nExclusion Criteria:\n\n* Patients in the CARES registry who have a traumatic cause of cardiac arrest.",{"count":65,"type":21},128,[24],"The overall goal of this project is to design, develop, and pilot test an emergency healthcare drone delivery system suitable for rural communities that can deliver AEDs to out-of-hospital cardiac arrest (OHCA) locations more rapidly than can be achieved with current first responder and EMS systems. The goal is to determine whether this method of AED delivery can be achieved rapidly enough to justify a future clinical trial directly testing its ability to improve OHCA survival.",[69,27],"Cardiac Arrest",[71,72],"Drone","Automated External Defibrillator","2026-05-13",{"date":75,"type":48},"2026-05-14",{"date":77,"type":48},"2025-09-08",{"date":79,"type":21},"2027-03-31",{"name":81,"class":82},"Duke University","OTHER",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":90,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":121},"100289553","mayo-avc-registry-and-biobank-100289553","NCT03049254","Mayo AVC Registry and Biobank","Identification of Novel Genetic Variants and Biomarkers of Disease Progression in Arrhythmogenic Cardiomyopathy","Inclusion Criteria:\n\n* Patients with a diagnosis of a non-MI SCA who survived\n* Patients with a non-MI SCD\n* Patient with a SCA associated with seizures, epilepsy, syncope, drowning and near-drowning, where a cardiomyopathy is suspected\n* Family member of a patient diagnosed with primary cardiomyopathy (including HCM, idiopathic DCM, AVC)\n\nExclusion Criteria:\n\n* Patients with a clear, unambiguous known cause of SCA or SCD such as myocardial infarction or heart failure secondary to ischemic heart disease\n* Significant coronary artery disease (Epicardial coronary artery stenosis \\>50%) which can explain degree of LV dysfunction\n* Those unwilling to provide written consent or assent",true,{"count":92,"type":21},1000,"OBSERVATIONAL","Arrhythmogenic ventricular cardiomyopathy (AVC) is a genetic condition which affects the heart and can lead to heart failure and rhythm problems, of which, sudden cardiac arrest or death is the most tragic and dangerous. Diagnosis and screening of blood-relatives is very difficult as the disease process can be subtle, but sufficient enough, so that the first event is sudden death.\n\nThe Mayo Clinic AVC Registry is a collaboration between Mayo Clinic, Rochester, USA and Papworth Hospital, Cambridge University Hospitals, Cambridge, UK. The investigators aim to enroll patients with a history of AVC or sudden cardiac death which may be due to AVC, from the US and UK. Family members who are blood-relatives will also be invited, including those who do not have the condition. Data collected include symptoms, ECG, echocardiographic, MRI, Holter, loop recorder, biopsies, exercise stress testing, blood, buccal and saliva samples.\n\nObjectives of the study:\n\n1. Discover new genes or altered genes (variants) which cause AVC\n2. Identify biomarkers which predict (2a) disease onset, (2b) disease progression, (2c) and the likelihood of arrhythmia (ventricular, supra-ventricular and atrial fibrillation)\n3. Correlate genotype with phenotype in confirmed cases of AVC followed longitudinally using clinical, electrocardiographic and imaging data.\n4. Characterize desmosomal changes in buccal mucosal cells with genotype and validate with gold-standard endomyocardial biopsies",[96,97,98,99,27,100,101,102,103,104,105,106,107,108,109,110,111],"Arrhythmogenic Right Ventricular Cardiomyopathy","Cardiomyopathies","Heart Diseases","Cardiovascular Diseases","Sudden Cardiac Death","Arrhythmogenic Right Ventricular Dysplasia","Arrhythmogenic Ventricular Cardiomyopathy","Familial Dilated Cardiomyopathy","Cardiovascular Abnormalities","Sarcoidosis","Cardiac Arrhythmia","Cardiac Sarcoidosis","Myocarditis","Inflammatory Cardiomyopathy","Ventricular Tachycardia","Right Ventricular Outflow Tract Ventricular Tachycardia","2026-04-22",{"date":114,"type":48},"2026-04-27",{"date":116,"type":48},"2018-02-09",{"date":118,"type":21},"2027-03",{"name":120,"class":82},"Mayo Clinic",2,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":90,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":132,"conditions":133,"keywords":134,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":56},"100627698","ai-guided-prediction-and-treatment-of-cardiac-arrest-100627698","NCT07452016","AI-guided Prediction and Treatment of Cardiac Arrest","Improving Cardiac Arrest Outcomes Using Artificial Intelligence Guided Precision Treatments","Inclusion Criteria:\n\n* Adult (18 years of age or older) EMS providers (Simulation trial)\n* Adult (18 years of age or older) patients have attempted resuscitation from out-of-hospital SCA of any etiology (Clinical trail)\n\nExclusion Criteria:\n\n* Non-English-speaking providers\n* Providers who do not care for cardiac arrest patients\n* Prisoners\n* Pediatric patients under age of 18\n* DNR\u002FDNI\n* No resuscitation attempted (declared deceased in field by EMS)",{"count":130,"type":21},68,[24],"Sudden cardiac arrest is a major health problem, and most people don't survive. One big reason is that even if resuscitation is successful, people commonly have recurrent cardiac arrests (rearrest). Right now, it is not possible to accurately predict a rearrest or prevent it. The investigators have developed a machine learning device that uses the heart tracing (ECG) to predict when and why a rearrest occurs. The investigators plan to test if it will accurately and effectively help EMS providers predict rearrest and provide timely treatment to increase survival after cardiac arrest. To determine if this machine learning device will work in the real world, the investigators need to find out if there are barriers to using it, and whether EMS providers will think it is useful and will help them improve the care of patients who have a cardiac arrest. The investigators will first test the device in live simulated cardiac arrest scenarios to see if the providers can use it and if they find the device potentially valuable in taking care of patients. In a second study, the investigators will test how accurate the device is in predicting if a cardiac arrest will happen again in patients who have just been brought back to life after a cardiac arrest. EMS providers will attach the device, but it will only work in the background. EMS will take care of patients as they normally would, without using or knowing what the device says. To see if the device is accurate at predicting another cardiac arrest, the investigators will analyze the results offline, and compare what the device says to what actually happens to the patient. By comparing what the device predicts to what actually happens, the investigators can see how well it predicts another cardiac arrest and estimate how it might improve treatment of patients.",[27],[135,136,137,138,139,140,141],"cardiac arrest","sudden cardiac death","machine learning","rearrest","ventricular fibrillation","ventricular tachycardia","pulseless electrical activity","NOT_YET_RECRUITING","2026-03-12",{"date":145,"type":48},"2026-03-16",{"date":147,"type":21},"2026-08",{"date":149,"type":21},"2029-06",{"name":151,"class":82},"MetroHealth Medical Center",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":160,"enrollmentInfo":161,"targetDuration":163,"studyType":93,"phases":4,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":183},"100627153","validation-of-sudden-cardiac-arrest-risk-factors-in-patients-with-cad-100627153","NCT07444931","Validation of Sudden Cardiac Arrest Risk Factors in Patients With CAD","Validation of Sudden Cardiac Arrest Risk Factors in Patients With CAD - CVDLINK Clinical Validation Study.","SCAR","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Ability to give informed consent\n* Imaging confirmed diagnosis within the past 12 months (coronary artery angiography or contrast enhanced coronary computed tomography)\n\n  •\\>50% of stenosis and\u002For fractional flow-reserve \\\u003C0.8 verified by selective coronary angiography or by contrast enhanced coronary computed tomography (CT) or type I MI with atherosclerotic origin (despite stenosis percentage)\n* Patients may be recruited during index event visit (out-patient clinic visit, invasive procedure, hospitalization) (or if logistically possible recall patients previously diagnosed within 12 months)\n\nExclusion Criteria:\n\n* Age \\> 75 years of age\n* Clinically significant previously treated valvular heart disease or requiring operative (surgical or endovascular) treatment within following three months\n* Diagnosed severe neurodegenerative disease (ALS, myositis, multiple sclerosis, or Parkinson's disease) or known impaired cognitive function (MMSE \\\u003C23)\n* Known developmental disability impairing legal ability to give written consent\n* Serious\u002Factive malignancy with possibly reduced life expectancy of \\\u003C1 year (estimated by a physician)\n* Inability to give written consent for some other reason\n* Other significant cardiac condition severely linked to the risk of fatal ventricular arrhythmia (for example ARVCD, non-ischemic DCM, HCM or genetic long or short QT syndrome)\n* Other cardiac disease with \\\u003C1 years of life expectancy\n* Do-Not-Resuscitate (DNR) order made due to any reason\n* Previously done or planned cardiac, renal, or liver transplant\n* Participation in another clinical trial where the active treatment","75 Years",{"count":162,"type":21},1500,"1 Year","Long-term sudden cardiac death (abbreviation: SCAR) focuses on improving the predictability of sudden cardiac death (SCD) in patients diagnosed with coronary artery disease. The aim of the study is to determine the predictive value of measurable biological variables (including genetic factors, cardiac electrical activity, biological markers measured from circulation, and coronary artery anatomy) as well as the patients' psychosocial factors in predicting SCDs.\n\nThe purpose of this study is the identification of a subgroup of coronary artery disease patients at sufficiently high risk in whom it may be possible to prevent sudden cardiac arrests and subsequent deaths using implantable cardioverter-defibrillators. The study is intended to establish a clear foundation for future interventional studies targeting high-risk coronary artery disease patients.\n\nThe primary endpoint of the study is SCD\u002Fsudden cardiac arrest (SCA) or a comparable malignant arrhythmic event (i.e., resuscitation). Secondary endpoints include other major cardiovascular events occurring during the follow-up period (such as cerebrovascular events, myocardial infarctions, revascularizations, and new arrhythmias like atrial fibrillation following procedures or after the patient has been discharged following recruitment) or the occurrence and mortality of other significant life-threatening diseases (such as cancer). Secondary endpoints also include poor success in secondary prevention, which can be assessed through completed medication purchases and the achievement of secondary prevention goals.\n\nThis observational, prospective study includes collecting multimodal data from hospitals in Finland (TAUH), Israel (HYMC), Moldova (IMSP) and Romania (UMFCD). Each participating institution has followed a process structured by Tampere Heart Hospital (TAUH) for securing permissions in line with EU and national regulations.",[166,27,100],"Coronary Arterial Disease (CAD)",[168,169,170,171,172,173],"Coronary artery disease","Sudden cardiac arrest","Sudden cardiac death","post operative atrial fibrillation","genetics","risk factors","2026-03-02",{"date":176,"type":48},"2026-03-03",{"date":178,"type":48},"2025-01-05",{"date":180,"type":21},"2027-12-31",{"name":182,"class":82},"Tampere Heart Hospital",3,{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":194,"briefSummary":196,"conditions":197,"keywords":201,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":215},"100349185","phase-4-epinephrine-dose-optimal-versus-standard-evaluation-trial-100349185","NCT03826524","Epinephrine Dose: Optimal Versus Standard Evaluation Trial","CanROC Epinephrine Dose: Optimal Versus Standard Evaluation Trial (CanROC EpiDOSE Trial)","EpiDOSE","Inclusion Criteria:\n\n* Out-of-hospital cardiac arrest treated by paramedics\n* Initial recorded cardiac rhythm of VF or pulseless VT, or, AED shock on first analysis administered or witnessed by EMS (paramedic or fire)\n* Established intravenous vascular access\n\nExclusion Criteria:\n\n* Known or apparent age \\\u003C18 years\n* Initial recorded cardiac rhythm of VF or pulseless VT, or, AED shock on first analysis administered or confirmed by paramedics\n* Cardiac arrest due to an obvious non-cardiac primary cause (e.g. blunt or penetrating trauma, exsanguination, burns, drug overdose, drowning, anaphylaxis, sudden asphyxiation, etc.)\n* Administration of intramuscular, endotracheal tube, or intraosseous epinephrine\n* Prisoners or persons in police custody\n* Known allergy or sensitivity to epinephrine",{"count":193,"type":21},3790,[195],"PHASE4","The objective of this randomized controlled trial is to evaluate the effectiveness of a low cumulative dose of epinephrine compared to a standard cumulative dose of epinephrine during resuscitation from ventricular fibrillation (VF) or ventricular tachycardia (VT) in adult out-of-hospital cardiac arrest (OHCA) patients.",[198,27,199,200],"Cardiac Arrest, Out-Of-Hospital","Ventricular Fibrillation","Ventricular Tachycardia-Pulseless",[202,203,204,205],"out-of-hospital cardiac arrest","sudden cardiac arrest","epinephrine","randomized controlled trial","2025-12-09",{"date":208,"type":48},"2025-12-11",{"date":210,"type":48},"2023-05-24",{"date":212,"type":21},"2028-12",{"name":214,"class":82},"Unity Health Toronto",8,{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":223,"targetDuration":225,"studyType":93,"phases":4,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":56},"100449662","assure-wcd-clinical-evaluation---post-approval-study-ace-pas-100449662","NCT05135403","ASSURE WCD Clinical Evaluation - Post Approval Study (ACE-PAS)","ACE-PAS","Inclusion Criteria:\n\n* Adult patient prescribed the ASSURE wearable cardioverter defibrillator\n* Provided written informed consent to participate in the ASSURE Patient Registry\n\nExclusion Criteria:\n\n* Patients who do not meet the Inclusion criteria",{"count":224,"type":21},5179,"3 Months","Active surveillance study using real-world data collected in the ASSURE Patient Registry. Outcome measures are based on analysis of ASSURE Registry data including data recorded by the WCD then annotated by clinical experts in electrophysiology.",[27],"2025-08-25",{"date":230,"type":48},"2025-09-02",{"date":232,"type":48},"2021-11-20",{"date":234,"type":21},"2025-10-01",{"name":236,"class":237},"Kestra Medical Technologies, Inc.","INDUSTRY",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":90,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":248,"conditions":249,"keywords":253,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":56},"100594064","using-heart-electrical-signals-to-study-how-well-treatments-prevent-dangerous-heart-rhythms-in-active-people-100594064","NCT07014579","Using Heart Electrical Signals to Study How Well Treatments Prevent Dangerous Heart Rhythms in Active People","Utilizing LifeMap To Investigate Malignant Arrhythmia Therapeutic Efficacy in Athletes","ULTIMATE-A","Inclusion Criteria:\n\n* Age 18 and over.\n* Participates in regular physical activity for at least 3 hours or greater weekly.\n* Having Implantable cardioverter defibrillator insitu (cases).\n* Having a cardiac pacemaker (control).\n* Having no cardiac device (control).\n* Sufficient capacity and agreement to participate orally and signed written consent forms.\n* Understanding of written and spoken English language.\n\nExclusion Criteria:\n\n* Pregnancy, as detected by positive urine pregnancy test result.\n* Inability to comply with study protocols.\n* Any iatrogenic cardiac pathology (stents, CABG etc).\n* Unstable ventricular tachycardia (\\>30 seconds).\n* Any unstable malignant arrhythmia.\n* Fever or presence of a clinically diagnosed febrile illness",{"count":247,"type":21},40,"The goal of this observational study is to learn if two specific heart electrical signal patterns can help in detecting the risk of dangerous heart rhythms in athletes, and to see if exercise-based tests can be used instead of invasive hospital procedures to record this electrical signals.\n\nThe main questions it aims to answer are:\n\n1. Can special ECG action potential duration markers (R2I2 and PERS) identify athletes who are at higher risk of sudden heart rhythm problems.\n2. Can an exercise test give the same information as a non-invasive electrophysiology study.\n\nResearchers will compare athletes who have an implanted heart device (ICD) with athletes who do not, to see if there are differences in these heart signals.\n\nParticipants will undergo:\n\n1. ECG recordings during rest and exercise.\n2. If they have an ICD or pacemaker, an ECG will be recorded during a non invasive stimulation.\n3. A continuous 24 hour ECG.",[250,27,251,252,199],"Inherited Cardiac Conditions","Ventricular Arrhythmia","Athlete",[254,255,256,257,251,199,100],"ULTIMATE-Athlete","LifeMap","R2I2","PERS","2025-06-09",{"date":260,"type":48},"2025-06-11",{"date":262,"type":21},"2025-06-01",{"date":264,"type":21},"2026-07-31",{"name":266,"class":82},"University of Leicester",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":273,"targetDuration":275,"studyType":93,"phases":4,"briefSummary":276,"conditions":277,"keywords":278,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":56},"100427037","heartstart-hs1-defibrillator-event-registry-100427037","NCT04840797","HeartStart HS1 Defibrillator* Event Registry","Inclusion Criteria:\n\n* Have been suspected of a circulatory arrest for any cause.\n* Have had HeartStart HS1 Defibrillator with electrodes:\n\nAdult SMART Pads Cartridge \\[REF: M5071A\\], Infant\u002FChild SMART Pads Cartridge (REF:M5072A) applied to their body and powered up with HS1 battery (Model M5070A), regardless of whether a defibrillation shock was delivered\n\nExclusion Criteria:\n\n* Subjects will be excluded if any of the following are present:\n* AED or pad use other than the HeartStart HS1 Defibrillator with above referenced Philips electrode pads. Note: Use of a device other than the Philips HeartStart HS1 AED does not preclude enrollment if the AED or an Advanced Life Support defibrillator was used after the HeartStart HS1 AED.\n* AED used for training purposes.",{"count":274,"type":21},1400,"1 Day","A Prospective study on the performance and safety of the HeartStart OnSite (Model M5066A) \\& HeartStart Home (Model M5068A) Defibrillator device data.",[27],[279,280,281],"AED","Post -Market","Cardiology","2025-02-25",{"date":284,"type":48},"2025-02-26",{"date":286,"type":48},"2021-02-25",{"date":288,"type":21},"2027-12",{"name":290,"class":237},"Philips Clinical & Medical Affairs Global",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":297,"targetDuration":275,"studyType":93,"phases":4,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":300,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":304,"locationsCount":56},"100381764","heartstart-frx-defibrillator-event-registry-100381764","NCT04250857","HeartStart FRx Defibrillator Event Registry","Inclusion Criteria:\n\n* Subjects accepted into the study must: have been suspected of a circulatory arrest for any cause\n* Have had HeartStart FRx AED with electrodes: HeartStart SMART PADS II applied to their body and powered up, regardless of whether a defibrillation shock was delivered\n\nExclusion Criteria:\n\n* AED or pad use other than the HeartStart FRx AED with electrodes : HeartStart SMART PADS II\n* AED used for training purposes.",{"count":274,"type":21},"This post market clinical follow-up study is a multi-center, non-randomized, unblinded, observational registry of the performance of the FRx Automated external defibrillator (AED) used in conjunction with electrodes with or without use of the infant\u002Fchild key. The registry is focused only on on post-event data collection and does not prescribe any device usage. This registry has several safeguards in place to prevent against selections bias, including enrollment of all participants who have pads placed. This registry will evaluate the safety and verify the clinical performance of the device in relation to its claims, when used in accordance with the Device Manual.",[27],{"date":284,"type":48},{"date":302,"type":48},"2019-11-04",{"date":288,"type":21},{"name":290,"class":237},{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":313,"targetDuration":4,"studyType":22,"phases":315,"briefSummary":316,"conditions":317,"keywords":321,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":4},"100577980","the-osiris-ecpr-trial-100577980","NCT06805344","The OSIRIS ECPR Trial","Out-of-hospital Refractory Cardiac Arrest Treated with Extracorporeal Cardiopulmonary Resuscitation","OSIRIS","Inclusion Criteria:\n\n1. Age ≥18 and ≤ 70 years presumed or known\n2. Witnessed OHCA\n3. Bystander CPR provided\n4. Presumed cardiac or unknown cause\n5. An initial documented shockable rhythm of VF (ventricular fibrillation) or pulseless VT (ventricular tachycardia)\n6. Minimum of ≥ 10 min of ACLS without ROSC or at least ≥ 3 defibrillations in ongoing VF\u002Fpulseless VT\n7. Body morphology able to accommodate a mechanical chest compression device\n8. ECPR team and intensive care unit (ICU) capacity in the receiving center available\n9. Estimated transfer time from the scene to the hospital ≤ 30 minutes or to the scene ≤ 30 minutes\n10. Eligible for intensive care without restrictions or limitations\n\nExclusion Criteria:\n\n1. ACLS ≥ 30 minutes before randomization\n2. Known limitations in care or a Do Not Attempt to Resuscitate (DNAR) order\n3. Known severe disease making 90-day survival unlikely\n4. Known bleeding diathesis or acute or recent intracranial bleeding\n5. Known, obvious or suspected pregnancy\n6. Known pre-arrest severe cognitive dysfunction (mRS ≥ 4)\n7. Known hypothermia as a cause of cardiac arrest",{"count":314,"type":21},686,[24],"The OSIRIS trial is an investigator-initiated, multicenter, multinational, open-label, randomized controlled trial with a 2:1 concealed allocation of refractory out-of-hospital cardiac arrest (OHCA) patients to the extracorporeal cardiopulmonary resuscitation (ECPR) based approach versus the conventional cardiopulmonary resuscitation (CCPR) approach.",[69,199,318,27,319,320],"Out-Of-Hospital Cardiac Arrest","Extracorporeal Cardiopulmonary Resuscitation","Extracorporeal Membrane Oxygenation",[135,322,323,202],"extracorporeal cardiopulmonary resuscitation","extracorporeal membrane oxygenation","2025-01-30",{"date":326,"type":48},"2025-02-03",{"date":328,"type":21},"2025-02",{"date":330,"type":21},"2030-06",{"name":332,"class":82},"General University Hospital, Prague",{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":340,"targetDuration":342,"studyType":93,"phases":4,"briefSummary":343,"conditions":344,"keywords":347,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":56},"100577915","tampere-coronary-artery-disease-and-sudden-cardiac-arrest-study-100577915","NCT06804499","Tampere Coronary Artery Disease and Sudden Cardiac Arrest Study","CADSCA","Inclusion Criteria:\n\n1. Age \\> 18 years\n2. A patient who lives in the area of 'Wellbeing Services County of Pirkanmaa' and seeks treatment for coronary artery disease (CAD).\n3. CAD is diagnosed with invasive coronary angiogram or computed tomography angiogram (CTA) which is evaluated by cardiologists based on current guidelines for stenosis level evaluation and fractional flow reserve (FFR) results.\n4. An invasive coronary angiogram or CTA is done within three (3) months.\n5. Good or moderate everyday functional ability\n\nExclusion Criteria:\n\n1. Life expectancy \\\u003C1 months.\n2. A significant valvular heart disease treated previously (endovascular or surgical) or requires treatment (endovascular or surgical) in the next three (3) months.\n3. Previously implanted cardioverter-defibrillators (ICD) or will be implanted in the next three (3) months.\n4. An active malignancy (ongoing treatment for a solid tumour, metastatic solid tumour, fast progressing haematological malignancy, or equal malignant disease).\n5. A significant neurodegenerative disease (dementia, Mini-Mental State Examination (MMSE) \\\u003C23 or equivalenneurodegenerative disease affecting everyday functional ability, like ALS, myositis, prograded MS-disease or Parkinson's disease).\n6. Intellectual disability or a significant disability affecting cognitive functions\n7. Do-not-resuscitate (DNR) treatment decision\n\nSubgroup with blood samples:\n\nBlood samples are withdrawn from all study subjects under 76 years of age. Additionally, PaxGene samples are withdrawn from i) all study subjects under 65 years of age and ii) subjects between 65-76 years, if they have detected QRS-time\\>110ms in the latest ECG.",{"count":341,"type":21},4000,"15 Years","The goal of this observational study is to recognize clinical and genetic risk factors for sudden cardiac arrest (SCA) and death (SCD) in patients with coronary artery disease (CAD).\n\nThe main questions it aims to answer are:\n\nAre we able to recognize clinical or treatment-related risk factors for SCA or SCD? Can we identify new genetic risk factors for SCA or SCD in patients under 75 years?\n\nParticipants diagnosed with CAD answer a short survey about their medical history and socioeconomic status. A standard ECG addition to a five (5) minute ECG recording is taken from all the study subjects. In addition to a few short physiological tests (e.g. blood pressure, height, weight, grip strength), a blood sample is withdrawn from a selected group of study subjects.\n\nMedical healthcare records are used to follow all study subjects, and no follow-up visits are required.",[27,100,345,166,346],"Sudden Cardiac Death Due to Cardiac Arrhythmia","Acute Coronary Event",[136,203,348,349],"coronary artery disease","acute coronary syndrome","2025-01-27",{"date":326,"type":48},{"date":353,"type":48},"2025-01-13",{"date":355,"type":21},"2042-12-31",{"name":182,"class":82},{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":363,"eligibilityCriteria":364,"healthyVolunteers":11,"sex":16,"minAge":365,"maxAge":366,"enrollmentInfo":367,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":369,"conditions":370,"keywords":371,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":390},"100565437","sudden-cardiac-arrest-related-to-sport-in-young-and-value-of-the-genetic-assessment-a-french-prospective-register-100565437","NCT06642168","Sudden Cardiac Arrest Related to Sport in Young and Value of the Genetic Assessment: a French Prospective Register","Registre Prospectif Français Des Morts Subites Chez Des Sportifs Jeunes","RESOUDRE","Inclusion Criteria:\n\n* Victims of SCA:\n\n  * Aged between 12 and 35 years\n  * No known cardiovascular pathology\n  * Experienced a sudden and non-traumatic SCA during or within one hour of participating in sports activities (leisure, training, or competition)\n  * For resuscitated victims (SCA group): A person or legal representative who does not oppose participation in the research after being informed about the study (including individuals, organs, or authorities responsible for assisting or representing them if they are unable to express their wishes).\n  * For non-resuscitated victims (SCD group): A person who has not formally objected to the reuse of their medical data during their lifetime.\n* First-Degree Relatives:\n\n  * A person or legal representative who does not oppose participation in the research after being informed about the study (including individuals, bodies, or authorities responsible for assisting or representing them if they are unable to express their wishes).\n\nNon-Inclusion Criteria:\n\n* For resuscitated SCA cases, individuals weighing less than 20 kg\n* Victims or legal representatives who are subject to legal protection or deprived of their liberty","12 Years","35 Years",{"count":368,"type":21},80,"The increased risk of sudden cardiac arrest (SCA) or sudden cardiac death (SCD) related to vigorous physical activity is well-documented. Currently, for young victims (under 35 years) of SCA\u002FSCD, no etiology is found in 40 to 50% of cases after a standard medical assessment, leading to two important consequences. For the victim's family, it is difficult to understand and accept this tragic event, and the risk of it occurring in another family member is a source of concern. Medically, the absence of a known cause limits the ability to effectively prevent such events.\n\nThe RESOUDRE study will be a national, prospective, observational registry of young victims (12-35 years) of sports-related SCA\u002FSCD. All cases will undergo the recommended etiological assessment, including autopsy for SCA cases, along with whole exome genetic analysis and toxicological testing. In the event a genetic pathology is identified, a genetic evaluation will be offered to other family members, and appropriate medical care will be provided if necessary. The results of this study could significantly reduce the number of unexplained sport-related SCA\u002FSCD cases and aid in preventing these incidents among affected families.",[27,100],[372,373,374,375,376,377,378,379,380],"Sport related sudden cardiac arrest","Sport related sudden cardiac death","Young athlete","Etiological Diagnosis","Autopsy","Genetic","Toxicology","Hereditary Cardiac disease","Prevention","2025-01-07",{"date":383,"type":48},"2025-01-08",{"date":385,"type":48},"2024-10-11",{"date":387,"type":21},"2028-01-11",{"name":389,"class":82},"Rennes University Hospital",26,{"id":392,"slug":393,"hasResults":11,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":11,"sex":16,"minAge":365,"maxAge":398,"enrollmentInfo":399,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":401,"conditions":402,"keywords":403,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":56},"100400418","hs-students-mandatory-universal-student-instruction-in-cpr-appraised-learning--is-the-mandate-working-100400418","NCT04493970","HS Students Mandatory Universal Student Instruction in CPR Appraised Learning- Is the Mandate Working?","Assessment of Factors Impacting High School Students Mandatory Universal Student Instruction in Cardiopulmonary Resuscitation Appraised Learning- Is the Mandate Working? (The High School MUSICAL Study)","Inclusion Criteria:\n\n* High school students completing voluntary survey\n\nExclusion Criteria:\n\n* Inability to give consent\n* Inability to complete survey","25 Years",{"count":400,"type":21},5000,"This study will help to provide better input to state health and education departments to improve the processes for CPR education. This will also help the EP council explore the opportunities to partner with other professional societies and other stake holders that have interest in this topic. Engagement of private-public partnerships for improving overall CPR education.",[27],[404,405],"CPR Education","High School Students","2024-10-23",{"date":408,"type":48},"2024-10-26",{"date":410,"type":48},"2021-02-26",{"date":412,"type":21},"2024-10",{"name":414,"class":82},"Kansas City Heart Rhythm Research Foundation"]